Data To Be Presented At ACR/ARHP 2016 Annual Meeting Show Amgen's Ongoing Commitment To Therapies For Patients With Serious Inflammatory And Bone Diseases
21 Abstracts to be Featured Provide Real-World and Disease State Insights, Highlight Clinical and Health Economic Impact of Rheumatologic Diseases and Osteoporosis
THOUSAND OAKS, Calif., Nov. 7, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from multiple studies related to Enbrel® (etanercept), Prolia® (denosumab) and AMJEVITA™ (adalimumab-atto), as well as investigational candidates, including ABP 710 (infliximab biosimilar candidate) and romosozumab, at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Wa...
Source: Amgen News Release - November 7, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Approves Expanded Use Of ENBREL ® (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis
First and Only Systemic Drug Approved in the U.S. to Treat Children Affected by This Serious Inflammatory Disease
THOUSAND OAKS, Calif., Nov. 4, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of ENBREL® (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.
"As many parents of children with moderate-to-severe plaque psoriasis can tell you, there is a need for FDA approved...
Source: Amgen News Release - November 4, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Approves Expanded Use of Enbrel (etanercept) to Treat Children with Chronic Moderate-To-Severe Plaque Psoriasis
THOUSAND OAKS, Calif., Nov. 4, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of Enbrel (etanercept),... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 4, 2016 Category: Drugs & Pharmacology Source Type: news
Erelzi (etanercept-szzs) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 12, 2016 Category: Drugs & Pharmacology Source Type: news
A Push to Lower Drug Prices That Hit Insurers and Employers the Hardest
Seeking to force drug price competition in an expensive category, the company wants insurers to cover fewer anti-inflammatory drugs, at least as a first-line treatment. (Source: NYT Health)
Source: NYT Health - September 8, 2016 Category: Consumer Health News Authors: KATIE THOMAS Tags: Express Scripts Inc Drugs (Pharmaceuticals) Health Insurance and Managed Care Prices (Fares, Fees and Rates) Enbrel (Drug) Humira Source Type: news
New Version of RA Drug Enbrel: FAQ
Title: New Version of RA Drug Enbrel: FAQCategory: Health NewsCreated: 9/2/2016 12:00:00 AMLast Editorial Review: 9/2/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - September 2, 2016 Category: Rheumatology Source Type: news
New Version of RA Drug Enbrel: FAQ
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 2, 2016 Category: Journals (General) Source Type: news
New Version of RA Drug Enbrel: FAQ
The FDA cleared the way for what is hoped may be a more affordable version of the popular arthritis drug Enbrel. Tuesday the agency approved Erelzi (etanercept-szzs), a "biosimilar" to Enbrel. (Source: WebMD Health)
Source: WebMD Health - September 1, 2016 Category: Consumer Health News Source Type: news
Monthly News Roundup - August 2016
FDA Approves Erelzi: Sandoz ’s Biosimilar For Enbrel
A third U.S. biosimilar has been FDA-approved; this time it’s Erelzi (etanercept-szzs), a biosimilar to Amgen’s tumor necrosis factor (TNF) blocker Enbrel. Sandoz’s Erelzi is the first... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 31, 2016 Category: Pharmaceuticals Source Type: news
FDA Approves New Biological Drug for RA
Erelzi is a biosimilar for Enbrel (Source: WebMD Health)
Source: WebMD Health - August 31, 2016 Category: Consumer Health News Source Type: news
FDA Approves Erelzi Biosimilar for Enbrel
WEDNESDAY, Aug. 31, 2016 -- A new biological drug to treat rheumatoid arthritis and other inflammatory diseases has been approved by the U.S. Food and Drug Administration.
The drug Erelzi (etanercept-szzs) is a " biosimilar " to Enbrel (etanercept),... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 31, 2016 Category: Journals (General) Source Type: news
FDA Approves New Biological Drug for Rheumatoid Arthritis
WEDNESDAY, Aug. 31, 2016 -- A new biological drug to treat rheumatoid arthritis and other inflammatory diseases has been approved by the U.S. Food and Drug Administration.
The drug Erelzi (etanercept-szzs) is a " biosimilar " to Enbrel (etanercept),... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 31, 2016 Category: Journals (General) Source Type: news
Novartis bid to sell new biosimilar crimped by U.S. court battles
ZURICH (Reuters) - Novartis has won U.S. approval for a copy of Amgen's blockbuster arthritis drug Enbrel, but the Swiss drugmaker's bid to muscle in on the medicine's $4.7 billion in annual U.S. revenue remains blocked by court battles. (Source: Reuters: Health)
Source: Reuters: Health - August 31, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Approves Etanercept Biosimilar
(MedPage Today) -- Erelzi will be licensed for all Enbrel ' s indications (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - August 31, 2016 Category: Dermatology Source Type: news
FDA Approves Erelzi (etanercept-szzs), a Biosimilar to Enbrel
August 30, 2016 -- The U.S. Food and Drug Administration today approved Erelzi, (etanercept-szzs) for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998.
Erelzi is administered by... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 31, 2016 Category: Drugs & Pharmacology Source Type: news
